Description: Public Joint-Stock Company "Pharmsynthez', a pharmaceutical company, researches, manufactures, and distributes officinal and generic active pharmaceutical ingredients in Russia and CIS countries. The company offers officinal medicines, including Neovir, Segidrin, Fenasid, and Penkrofton that are used in oncology, gynecology, treatment of immune deficiencies, and tuberculosis. Public Joint-Stock Company "Pharmsynthez' has partnership with HiFiBiO Therapeutics Inks for the clinical development and commercialization of its SARS-CoV-2 neutralizing antibody in Russia. Public Joint-Stock Company "Pharmsynthez' was founded in 1996 and is based in St. Petersburg, Russia.
Home Page: www.pharmsynthez.com
25 Krasnovo Kursanta Str
Saint Petersburg,
197110
Russia
Phone:
7 812 329 8080
Officers
| Name | Title |
|---|---|
| Mr. Petr Vladimirovich Kurglyakov | Director Gen. |
| Barkanova Anna Borisovna | Chief Accountant |
| Mr. Yury Iosifovich Maylis | Chief Power Engineer |
| Surkov Kirill Gennadievich | Head of Research & Department and Member of Audit Commission |
Exchange: MCX
Country: RU : Russian Federation
Currency: Russian Rouble (₽)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.4043 |
| Price-to-Sales TTM: | 3.0047 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |